Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 1.00 |
| ▸ | MAOA | P21397 | 7/20 | 1.00 |
| ▸ | F3 | P13726 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | XDH | P47989 | 2/20 | 0.68 |
| ▸ | BCHE | P06276 | 1/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.68 |
| ▸ | P4HB | P07237 | 1/20 | 0.68 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | KRAS | P01116 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10658787 | 1.00 | MAOB (1.00) | MAOBMAOAF3MAPTALDH1A1 | |
| SCHEMBL14435873 | 1.00 | MAOB (1.00) | MAOBMAOAF3MAPTALDH1A1 | |
| SCHEMBL31326032 | 1.00 | MAOB (1.00) | MAOBMAOAF3MAPTALDH1A1 | |
| SCHEMBL6733848 | 0.88 | MAOB (0.85) | MAOBMAOAMAPTALDH1A1BCHE | |
| SCHEMBL6733854 | 0.88 | MAOB (0.85) | MAOBMAOAMAPTALDH1A1BCHE | |
| SCHEMBL8160140 | 0.88 | MAOB (0.78) | MAOBMAOAF3MAPTALDH1A1 | |
| SCHEMBL14318106 | 0.88 | MAOB (0.78) | MAOBMAOAMAPTALDH1A1RAB9A | |
| SCHEMBL7194437 | 0.88 | MAOB (0.78) | MAOBMAOAF3MAPTALDH1A1 | |
| SCHEMBL7194081 | 0.88 | MAOB (0.78) | MAOBMAOAF3MAPTALDH1A1 | |
| 4,4'-Dimethoxychalcone SCHEMBL978243 | 0.87 | F3 (1.00) | MAOBMAOAF3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3333153-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2018-06-13 | — | — | EP | disclosed |
| US-20140171503-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | HUMAN SERVICES (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2012174436-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-12-20 | — | — | WO | disclosed |
| US-4719174-A | USING ABSORPTIVE COMPOUND WHICH RELEASES ELECTRONS UPON EXPOSURE | FUJI PHOTO FILM CO., LTD. (JP) | 1988-01-12 | — | — | US | disclosed |
| US-4607006-A | Silver halide photographic light-sensitive material containing non-spectral sensitizing electron donative silver halide adsorptive compound | FUJI PHOTO FILM CO., LTD. (JP) | 1986-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171503-A1 | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | AR, NCOA1, NR5A1 | MAOB 3966/4885MAOA 4067/4885F3 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.